Clinithink, a London, UK-based company which offers healthcare and life sciences organizations clinical data insights through its patented CLiX natural language processing (NLP) platform, secured a growth-equity investment of undisclosed amount.
Backers included TT Capital Partners (TTCP) and the MSD Global Health Innovation Fund (GHI).
The company intends to use the funds to expand its global presence and continue to broaden its service offering.
Led by CEO Dr Chris Tackaberry, Clinithink provides technology that uses artificial intelligence (AI) technology to accurately ‘read’ and interpret up to two million clinical documents an hour, impacting patient care across the healthcare continuum. The solution compares a patient’s extracted phenotype with over 12,000 phenotypes and over 15,000 synonyms describing the characteristics of thousands of rare diseases and automates the review of a hospital’s clinical notes and connects physicians and patients with clinical trials.
Clinithink also helps biopharma and contract research organizations (CROs) with site selection and protocol optimization in order to accelerate drug development and get promising new therapies to patients by leveraging its solution to support real world data analysis.